

**DRUG UTILIZATION REVIEW (DUR) ANNUAL REPORT
FEDERAL FISCAL YEAR 2007
EXECUTIVE SUMMARY**

BACKGROUND

The Omnibus Budget Reconciliation Act (OBRA) of 1990 requires that, effective January 1, 1993, each State establish a Medicaid Drug Utilization Review (DUR) Program. The program must include both prospective and retrospective DUR to assure that prescriptions are appropriate, medically necessary, and are not likely to result in adverse medical results. To accomplish this objective, the law requires Medicaid DUR programs to screen, based upon explicit criteria, for therapeutic problems specified in the law (for example, drug-drug interactions, incorrect dosage and duration of therapy, therapeutic duplication), to develop and implement interventions to change drug use behavior, and to assess the outcome of the intervention.

ANNUAL REPORT

The law [Section 1927(g)(3)(D) of the Social Security Act] also requires State Medicaid agencies to prepare and submit, on an annual basis, a specified report to the Secretary of Health and Human Services that includes the following information:

- (1) A description of the nature and scope of the prospective and retrospective drug utilization review program;
- (2) A summary of the educational interventions used and an assessment of the effect of these educational interventions on the quality of care;
- (3) An estimate of the cost savings generated as a result of the DUR program. This report must identify costs of DUR and savings to the Medicaid drug program attributable to prospective and retrospective DUR.

The attached report fulfills that requirement for the Wisconsin Medicaid program.

HISTORY OF WISCONSIN MEDICAID DRUG UTILIZATION REVIEW PROGRAM

The state agency in the Wisconsin Department of Health and Family Services responsible for benefits administration is the Division of Health Care Access and Accountability (DHCAA). The DHCAA established a Medicaid Evaluation and Decision Support Drug Utilization Review (DUR) Project. Since September 1994, the Wisconsin Medicaid DUR Project has been administered by APS Healthcare in partnership with Health Information Designs, Inc. under a subcontract. Since September 1996, the primary contractor is Electronic Data Systems (EDS).

SUMMARY OF PROSPECTIVE AND RETROSPECTIVE DUR ACTIVITIES

Prospective DUR

The State of Wisconsin utilizes an on-line prospective DUR program that began in the second quarter of FFY 2002. Prior to this time, the Medicaid Program relied on pharmacists to provide these services. A summary of prospective DUR interventions for FFY 2007 is attached as Table 1.

Retrospective DUR

Retrospective DUR activities are performed by APS Healthcare (APS) utilizing software supplied by Health Information Designs, Inc. (HID), both of whom are subcontractors to EDS. Monthly DUR reviews are performed following receipt of paid claims tapes from EDS. Interrogation of drug claims against DUR Board-approved criteria generate patient profiles that are individually reviewed for clinical significance by the pharmacy staff of APS Healthcare. Criteria are developed jointly by APS and HID and are reviewed and approved by the DUR Board and recommended to DHCAA for approval. If a potential drug problem is discovered, intervention letters are sent to all providers who prescribed a drug relevant to the identified problem. Retrospective DUR criteria are tabulated in Table 2 of the report.

During FFY 2007, 6272 individual patient drug profiles were reviewed. Intervention letters and referrals were sent to 2728 prescribers concerning potential drug therapy problems involving 1935 patients. The number of cases reviewed and the interventions per month are illustrated in Appendix B.

DUR Board Activities

The current DUR Board is composed of nine members; three physicians, five pharmacists, and one nurse practitioner. In FFY 2007, James Vavra of the DHCAA served as chair of the board. A list of the 2007 DUR Board members appears as Appendix A.

The DUR Board meets four times annually. Additional materials are sent to Board members between meetings for review and action. Activities of the DUR Board included review and approval of DUR criteria, review and approval of educational material and interventions, and other recommendations to the DHCAA on drug-related issues.

Cost Savings

A cost savings analysis of drug costs associated with a recipient before and after a retrospective DUR letter intervention was prepared for FFY 2007. Payments for drugs were aggregated for six months before a DUR letter intervention and, after a 14-day wash out period, six months post intervention. Thus, the savings reflect a comparison of the amount paid for drugs before the intervention with those after the intervention. A comparison group of eligible recipients who have never received an intervention is used as a comparison group. The number of patients randomly selected equals the number of patients for whom an intervention was sent. Costs pre-

and post intervention are calculated from this group. The total cost difference from this group is subtracted from any cost savings in the intervention group to generate the final cost savings estimates. Appendix C includes each month's interventions separately. The total savings for this six-month comparison is \$755,624.

This analysis relies on completed claims data and reflects actual not projected savings. Also, the analysis does not project additional savings that may be realized greater than six months after the intervention.

Additional analyses were conducted to determine the cost savings resulting from prospective DUR alerts. These analyses looked for instances when a prescription was not filled as a result of a DUR alert. The claims database was queried to see whether a prescription was filled after a DUR alert was sent. For all alerts except early refill, the database was queried for one week following an alert. If the prescription was not filled within a week after the alert, it was considered not to have been filled and cost savings was calculated. For early refill alerts, cost savings was calculated only if the prescription was not filled within a calculated time period. This time period equals the days supply plus 25% of the days supply. (Thus, a prescription with an early refill alert for a 30 days supply would look to see if a claim for the drug was filled less than 38 days from the alert. If the prescription was not filled in that time frame, cost savings was calculated.) A summary of a typical week of cost savings is attached in Appendix C. Annualized savings is estimated at \$9.1 million.

Conclusion

The State of Wisconsin is in compliance with the DUR requirements specified in OBRA '90. Programs administered by the state provide direct cost savings to the overall Medicaid program.

The monthly retrospective DUR intervention cycle, the prospective DUR alerts, and the additional targeted DUR interventions provide a clinical oversight of the fee-for service Medicaid and SeniorCare recipients and provide the State of Wisconsin with significant cost savings.

Alert Volume for Prospective DUR

Pharmacy claims processed in 7 days	Total distinct ICN alerted	Actual response	% of all alerts	% claims receiving an alert
Sep-07	Sep-07	Sep-07	Sep-07	Sep-07
149004	93326			
AT Primary	20194	10114	21.64%	6.79%
DC/MC Primary	182	81	0.20%	0.05%
DD Primary	7071	3398	7.58%	2.28%
ER Primary	7371	1909	7.90%	1.28%
LR Primary	7166	3350	7.68%	2.25%
NS Primary	35769	17266	38.33%	11.59%
PA Primary	497	257	0.53%	0.17%
PG Primary	559	282	0.60%	0.19%
SR Primary	6955	3480	7.45%	2.34%
TD Primary	7562	3011	8.10%	2.02%

AT Additive Toxicity	NS Insufficient quantity
DC/MC Inferred disease contraindication	PA Patient age contraindication
DD Drug/drug interaction	PG Pregnancy alert
ER Early refill	SR Suboptimal regimen
LR Late refill	TD Therapeutic duplication

Prospective DUR
Pharmacist's action

Alert/Response	AT	DC/MC	DD	ER	LR	NS	PA	PG	SR	TD
MR-Medication review	36.1%	38.3%	34.5%	26.2%	32.2%	33.5%	27.6%	26.6%	33.6%	34.1%
R0-RPh consulted other source	13.4%	8.6%	13.7%	14.4%	11.8%	13.8%	18.7%	20.6%	13.4%	13.4%
M0-Prescriber consulted	12.3%	12.3%	14.1%	13.0%	8.4%	9.1%	18.3%	13.5%	11.5%	15.5%
AS-Patient assessment	11.7%	16.0%	11.5%	12.4%	12.6%	11.7%	17.1%	22.0%	12.1%	10.7%
00-No intervention	10.5%	3.7%	10.9%	11.2%	12.0%	14.9%	8.2%	5.7%	12.1%	9.8%
P0-Patient consulted	6.0%	8.6%	6.0%	10.6%	12.8%	8.3%	7.4%	8.2%	9.3%	6.0%
PH-Patient Medication HX	3.4%	4.9%	3.9%	2.4%	2.3%	2.6%	1.2%	0.7%	2.2%	3.5%
CC-Coordination of care	3.2%	1.2%	2.9%	5.0%	2.3%	3.1%	0.4%	0.4%	3.2%	3.6%
PE-Patient education	2.1%	6.2%	1.7%	3.8%	5.0%	1.9%	0.8%	2.1%	2.0%	2.0%
PM-Patient Monitoring	0.7%		0.4%	0.3%	0.3%	0.3%	0.4%		0.1%	0.8%
All others	0.7%		0.5%	0.7%	0.3%	0.8%		0.3%	0.7%	0.6%

Prospective DUR
Pharmacists's action

Alert/Response	AT	DC/MC	DD	ER	LR	NS	PA	PG	SR	TD
1B-Filled as is	86.4%	87.7%	87.3%	82.2%	87.0%	87.9%	88.3%	87.2%	87.6%	84.5%
1G-Filled with prescriber approval	5.1%	2.5%	5.4%	4.9%	3.6%	3.2%	5.1%	3.2%	4.7%	5.8%
00-Not specified	2.7%	1.2%	2.3%	2.9%	3.4%	3.6%	1.6%	2.1%	3.0%	2.8%
1A-Filled as is, False positive	2.6%	3.7%	2.4%	3.2%	2.4%	2.3%	3.9%	5.3%	2.0%	2.2%
3F-Therapy changed-cost increase	1.0%									
3K-Instructions understood	0.8%	1.2%	0.8%	1.0%	1.6%	0.7%		1.4%	0.5%	1.3%
1D-Filled with different directions	0.5%		0.1%	2.5%	0.1%	0.1%				0.2%
1C-Filled, different dose	0.2%	1.2%	0.1%	1.4%	0.1%	0.1%		0.4%	0.1%	1.0%
3N-Medication administered	0.2%		0.2%	0.4%	0.1%	0.1%			0.1%	0.1%
3B-Recommendation not accepted	0.1%		0.2%	0.2%	0.3%	0.8%	0.4%		0.8%	0.1%
1F-Filled, different quantity	0.1%		0.0%	0.1%	0.0%	0.6%			0.1%	
3A-Recommendation accepted	0.1%	2.5%	0.3%	0.4%	0.4%	0.1%			0.1%	0.1%
1E-Filled, different drug	0.0%		0.0%			0.0%				0.8%
3C-Discontinued drug	0.0%									0.0%
3D-Regimen changed	0.0%			0.3%						
3E-Therapy changed	0.0%			0.2%						0.2%
3G-Drug Therapy unchanged	0.0%		0.8%	0.3%	1.0%	0.0%	0.8%	0.4%	0.9%	0.9%
1K-Filled with different dosage form					0.1%					0.0%
3M-Compliance aid developed				0.1%		0.6%				

Calendar Year 2007 Retrospective DUR Interventions
Ranked by Volume

Criteria #	Utilization Category A	Utilization Category B		Total reviews	Total cases	Letters generated	Letters sent
85	NARCOTIC AGENTS		ER	471	53	139	132
2494	SEROTONIN REUPTAKE INHIBITORS	CYCLIC ANTIDEPRESSANT AGENTS	DD	454	49	89	66
561	ANTIPSYCHOTICS - ALL		TD	443	39	84	58
2810	ATYPICAL NEUROLEPTICS	DIABETES	DB	403	133	225	168
136	SEROTONIN REUPTAKE INHIBITORS		TD	393	40	77	71
1155	ESCITALOPRAM		HD	300	112	112	112
2499	STIMULANTS	HYPERTENSION	DC	231	42	87	75
1119	CYCLOBENZAPRINE		ER	201	81	84	79
535	NSAIDS		TD	190	51	97	85
1156	ESCITALOPRAM		TA	190	79	79	79
167	ANXIOLYTIC AGENTS		TD	188	40	85	77
474	ZOLPIDEM		HD	186	116	121	93
165	BENZO SEDATIVES		ER	170	6	7	6
605	ANALGESIC MIGRAINE MEDS	MIGRAINE	TA	138	34	45	43
1886	OXYBUTYNIN		TA	130	88	88	79
799	ACETAMINOPHEN		HD	126	72	133	132
88	ANXIOLYTIC AGENTS		ER	124	24	47	46
1537	CARDIOVASCULAR DRUGS	CORONARY HEART DISEASE INDICATORS	TA	123	55	59	54
2335	ATYPICAL NEUROLEPTICS		TA	123	62	65	44
1073	ANTIHISTAMINES (ALL)		TD	120	22	43	36
2382	TUSSIONEX		ER	120	43	58	49
684	BETA-AGONISTS (INHALED)		ER	111	20	26	17
16	NSAIDS	WARFARIN	DD	108	22	45	41
135	CYCLIC ANTIDEPRESSANT AGENTS		TD	103	13	27	27
1350	CITALOPRAM 20MG		ER	96	35	35	34
1860	DOXEPIN		TA	90	61	61	41
86	STIMULANTS		ER	87	8	16	15
95	ACE INHIBITORS/K+SPARING DIURETICS	POTASSIUM SUPPLEMENTS	DD	82	17	31	26
65	ANTIDEPRESSANT AGENTS	ANTICHOLINERGIC AGENTS	DD	81	20	41	26
2	AMIODARONE	WARFARIN	DD	79	11	23	20
454	ANTIPSYCHOTICS-ATYPICAL		TD	69	4	9	9
564	AMBIEN/SONATA/LUNESTA		ER	68	9	9	2
566	SONATA AND AMBIEN		HD	66	46	47	27
1352	VENLAFAXINE XR 75MG		ER	62	17	17	11
74	ACEI		TD	58	13	23	13
2497	ANTIDEPRESSANTS	PREGNANCY (WI ONLY)	PG	57	17	36	12
1364	OMEPRAZOLE 20MG		ER	52	33	33	33
1178	AMITRIPTYLINE		HD	47	24	26	26
3	AMIODARONE	CARDIAC GLYCOSIDES	DD	40	7	14	13
1356	ESOMEPRAZOLE 20MG		ER	37	30	30	30
2496	SEDATIVE AGENTS	PREGNANCY (WI ONLY)	PG	36	24	48	44
1358	PAROXETINE 20MG		ER	35	27	27	27

Calendar Year 2007 Retrospective DUR Interventions
Ranked by Volume

2493	ACEI	NSAID'S	DD	35	4	8	8
1120	CYCLOBENZAPRINE		HD	33	17	19	13
1306	ZOLPIDEM		HD	29	3	3	3
1557	SERTRALINE 50MG		ER	29	15	15	15
1362	LANSOPRAZOLE 15MG		ER	28	24	24	23
1334	DIURETICS	CONGESTIVE HEART FAILURE	MC	25	18	19	14
1820	CERTAIN ANTIHISTAMINES & ANTICHOLINERGICS		TA	25	11	11	10
185	NSAIDS	LITHIUM	DD	24	12	25	24
1871	TICLOPIDINE		TA	22	20	20	12
713	TRAMADOL		ER	15	11	11	8
1351	VENLAFAXINE XR 37.5MG		ER	14	9	9	9
544	BETA AGONIST	ASTHMA	TA	13	7	8	8
1372	FLUVOXAMINE 50MG		ER	13	8	8	8
1864	ALPRAZOLAM-DOSE		HD	12	11	12	10
2334	LONG-ACTING ADD/ADHD MEDS		TD	12	2	4	4
2472	HORMONE REPLACEMENT THERAPY	THROMBOEMBOLIC DISORDERS/DRUGS	DB	12	7	11	6
1625	ROSUVASTATIN-DOSE		ER	11	8	8	8
1164	CARDIO POST MI DRUGS	POST MYOCARDIAL INFARCTION	TA	9	8	8	8
1349	CITALOPRAM 10MG		ER	9	4	4	4
2495	NSAIDS	PREGNANCY (WI ONLY)	PG	9	4	9	0
2426	ANTICHOLINERGICS		TD	8	1	2	2
20	THIAZIDES	LITHIUM	DD	5	3	6	4
99	ANTIPSYCHOTIC AGENTS	ANTICONVULSANTS	DB	5	2	3	3
1357	PAROXETINE 10MG		ER	4	4	4	4
1869	DIPHENHYDRAMINE		TA	4	3	3	3
2492	BARBITURATES	ANTICOAGULANT AGENTS	DD	4	3	7	5
1369	SIMVASTATIN 20MG		ER	3	3	3	3
1556	SERTRALINE 25MG		ER	3	2	2	2
1818	LORAZEPAM-DOSE		HD	3	2	2	1
1361	PRAVASTATIN 40MG		ER	2	2	2	2
2498	ACEI	PREGNANCY (WI ONLY)	PG	2	1	2	1
49	CIMETIDINE	WARFARIN	DD	1	1	2	2
75	CALCIUM CHANNEL BLOCKERS		TD	1	1	2	2
1354	ATORVASTATIN 20MG		ER	1	1	1	1
1363	OMEPRAZOLE 10MG		ER	1	1	1	1
1368	SIMVASTATIN 10MG		ER	1	1	1	1

DB - DRUG-DRUG MARKER AND/OR DIAGNOSIS
DC - INFERRED DRUG DISEASE PRECAUTION
DD - DRUG-DRUG INTERACTIONS
HD - HIGH DOSE ALERT

MC - DRUG (ACTUAL) DISEASE PRECAUTION
PG - DRUG PREGNANCY ALERT
TA - THERAPEUTIC APPROPRIATENESS
TD - THERAPEUTIC DUPLICATION

Calendar Year 2007 Retrospective DUR Interventions
Ranked by Yield

Criteria #	Utilization Category A	Utilization Category B		Total reviews	Total cases	Letters generated	Letters sent	Yield	Letters per case
1357	PAROXETINE 10MG		ER	4	4	4	4	100.0%	1.0
1369	SIMVASTATIN 20MG		ER	3	3	3	3	100.0%	1.0
1361	PRAVASTATIN 40MG		ER	2	2	2	2	100.0%	1.0
49	CIMETIDINE	WARFARIN	DD	1	1	2	2	100.0%	2.0
75	CALCIUM CHANNEL BLOCKERS		TD	1	1	2	2	100.0%	2.0
1354	ATORVASTATIN 20MG		ER	1	1	1	1	100.0%	1.0
1363	OMEPRAZOLE 10MG		ER	1	1	1	1	100.0%	1.0
1368	SIMVASTATIN 10MG		ER	1	1	1	1	100.0%	1.0
1864	ALPRAZOLAM-DOSE		HD	12	11	12	10	91.7%	0.9
1871	TICLOPIDINE		TA	22	20	20	12	90.9%	0.6
1164	CARDIO POST MI DRUGS	POST MYOCARDIAL INFARCTION	TA	9	8	8	8	88.9%	1.0
1362	LANSOPRAZOLE 15MG		ER	28	24	24	23	85.7%	1.0
1356	ESOMEPRAZOLE 20MG		ER	37	30	30	30	81.1%	1.0
1358	PAROXETINE 20MG		ER	35	27	27	27	77.1%	1.0
1869	DIPHENHYDRAMINE		TA	4	3	3	3	75.0%	1.0
2492	BARBITURATES	ANTICOAGULANT AGENTS	DD	4	3	7	5	75.0%	1.7
713	TRAMADOL		ER	15	11	11	8	73.3%	0.7
1625	ROSUVASTATIN-DOSE		ER	11	8	8	8	72.7%	1.0
1334	DIURETICS	CONGESTIVE HEART FAILURE	MC	25	18	19	14	72.0%	0.8
566	SONATA AND AMBIEN		HD	66	46	47	27	69.7%	0.6
1860	DOXEPIN		TA	90	61	61	41	67.8%	0.7
1886	OXYBUTYNIN		TA	130	88	88	79	67.7%	0.9
2496	SEDATIVE AGENTS	PREGNANCY (WI ONLY)	PG	36	24	48	44	66.7%	1.8
1556	SERTRALINE 25MG		ER	3	2	2	2	66.7%	1.0
1818	LORAZEPAM-DOSE		HD	3	2	2	1	66.7%	0.5
1351	VENLAFAXINE XR 37.5MG		ER	14	9	9	9	64.3%	1.0
1364	OMEPRAZOLE 20MG		ER	52	33	33	33	63.5%	1.0
474	ZOLPIDEM		HD	186	116	121	93	62.4%	0.8
1372	FLUVOXAMINE 50MG		ER	13	8	8	8	61.5%	1.0
20	THIAZIDES	LITHIUM	DD	5	3	6	4	60.0%	1.3
2472	HORMONE REPLACEMENT THERAPY	THROMBOEMBOLIC DISORDERS/DRUGS	DB	12	7	11	6	58.3%	0.9
799	ACETAMINOPHEN		HD	126	72	133	132	57.1%	1.8
544	BETA AGONIST	ASTHMA	TA	13	7	8	8	53.8%	1.1
1557	SERTRALINE 50MG		ER	29	15	15	15	51.7%	1.0
1120	CYCLOBENZAPRINE		HD	33	17	19	13	51.5%	0.8
1178	AMITRIPTYLINE		HD	47	24	26	26	51.1%	1.1
2335	ATYPICAL NEUROLEPTICS		TA	123	62	65	44	50.4%	0.7
185	NSAIDS	LITHIUM	DD	24	12	25	24	50.0%	2.0
2498	ACEI	PREGNANCY (WI ONLY)	PG	2	1	2	1	50.0%	1.0
1537	CARDIOVASCULAR DRUGS	CORONARY HEART DISEASE INDICATORS	TA	123	55	59	54	44.7%	1.0

Calendar Year 2007 Retrospective DUR Interventions
Ranked by Yield

1349	CITALOPRAM 10MG		ER	9	4	4	4	44.4%	1.0
2495	NSAIDS	PREGNANCY (WI ONLY)	PG	9	4	9	0	44.4%	0.0
1820	CERTAIN ANTIHISTAMINES & ANTICHOLINERGICS		TA	25	11	11	10	44.0%	0.9
1156	ESCITALOPRAM		TA	190	79	79	79	41.6%	1.0
1119	CYCLOBENZAPRINE		ER	201	81	84	79	40.3%	1.0
99	ANTIPSYCHOTIC AGENTS	ANTICONVULSANTS	DB	5	2	3	3	40.0%	1.5
1155	ESCITALOPRAM		HD	300	112	112	112	37.3%	1.0
1350	CITALOPRAM 20MG		ER	96	35	35	34	36.5%	1.0
2382	TUSSIONEX		ER	120	43	58	49	35.8%	1.1
2810	ATYPICAL NEUROLEPTICS	DIABETES	DB	403	133	225	168	33.0%	1.3
2497	ANTIDEPRESSANTS	PREGNANCY (WI ONLY)	PG	57	17	36	12	29.8%	0.7
1352	VENLAFAXINE XR 75MG		ER	62	17	17	11	27.4%	0.6
535	NSAIDS		TD	190	51	97	85	26.8%	1.7
65	ANTIDEPRESSANT AGENTS	ANTICHOLINERGIC AGENTS	DD	81	20	41	26	24.7%	1.3
605	ANALGESIC MIGRAINE MEDS	MIGRAINE	TA	138	34	45	43	24.6%	1.3
74	ACEI		TD	58	13	23	13	22.4%	1.0
167	ANXIOLYTIC AGENTS		TD	188	40	85	77	21.3%	1.9
95	ACE INHIBITORS/K+SPARING DIURETICS	POTASSIUM SUPPLEMENTS	DD	82	17	31	26	20.7%	1.5
16	NSAIDS	WARFARIN	DD	108	22	45	41	20.4%	1.9
88	ANXIOLYTIC AGENTS		ER	124	24	47	46	19.4%	1.9
1073	ANTIHISTAMINES (ALL)		TD	120	22	43	36	18.3%	1.6
2499	STIMULANTS	HYPERTENSION	DC	231	42	87	75	18.2%	1.8
684	BETA-AGONISTS (INHALED)		ER	111	20	26	17	18.0%	0.9
3	AMIODARONE	CARDIAC GLYCOSIDES	DD	40	7	14	13	17.5%	1.9
2334	LONG-ACTING ADD/ADHD MEDS		TD	12	2	4	4	16.7%	2.0
2	AMIODARONE	WARFARIN	DD	79	11	23	20	13.9%	1.8
564	AMBIEN/SONATA/LUNESTA		ER	68	9	9	2	13.2%	0.2
135	CYCLIC ANTIDEPRESSANT AGENTS		TD	103	13	27	27	12.6%	2.1
2426	ANTICHOLINERGICS		TD	8	1	2	2	12.5%	2.0
2493	ACEI	NSAID'S	DD	35	4	8	8	11.4%	2.0
85	NARCOTIC AGENTS		ER	471	53	139	132	11.3%	2.5
2494	SEROTONIN REUPTAKE INHIBITORS	CYCLIC ANTIDEPRESSANT AGENTS	DD	454	49	89	66	10.8%	1.3
1306	ZOLPIDEM		HD	29	3	3	3	10.3%	1.0
136	SEROTONIN REUPTAKE INHIBITORS		TD	393	40	77	71	10.2%	1.8
86	STIMULANTS		ER	87	8	16	15	9.2%	1.9
561	ANTIPSYCHOTICS - ALL		TD	443	39	84	58	8.8%	1.5
454	ANTIPSYCHOTICS-ATYPICAL		TD	69	4	9	9	5.8%	2.3
165	BENZO SEDATIVES		ER	170	6	7	6	3.5%	1.0

Calendar Year 2007 Retrospective DUR Interventions
Ranked by Yield

DB - DRUG-DRUG MARKER AND/OR DIAGNOSIS
DC - INFERRED DRUG DISEASE PRECAUTION
DD - DRUG-DRUG INTERACTIONS
HD - HIGH DOSE ALERT
MC - DRUG (ACTUAL) DISEASE PRECAUTION
PG - DRUG PREGNANCY ALERT
TA - THERAPEUTIC APPROPRIATENESS
TD - THERAPEUTIC DUPLICATION